Further trials on GW's cannabis drugs
clinical trials for its cannabis-based medicines.
UK-based GW Pharmaceuticals is to expand phase three clinical trials for its cannabis-based medicines, reports FT.com.
The new trials are to involve around 600 patients and will be staged alongside the phase three trials already in progress. Trials to date have concerned the use of cannabis medicines for multiple sclerosis, cancer and nerve damage pain.
"The start of four new phase three clinical trials heralds the achievement of another key milestone in our progress towards first regulatory submission for our products," said Geoffrey Guy, executive chairman.
The company said that it plans to make its first submission for approval of the medicine, administered by an under-the-tongue spray, next year.
While possession of cannabis remains illegal in the UK, the pharmaceuticals company has been given a special licence to grow the drug. The British government is reported to have indicated a future amendment to current law so that cannabis-based medicines are allowed when the product is licensed.
